A new US biotech start-up, Kinaset Therapeutics, founded to develop new therapies for asthma, will have as its lead compound a novel pan-JAK inhibitor, KN-002, which is licensed from the UK inhalation specialist company Vectura Group plc and is expected to enter clinical studies in the first half of 2021.
Not only has Kinaset taken an exclusive global license to KN-002 (formerly Vectura’s VR588), the Medfield, MA-based biotech has also...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
